Draft:Abhishesh Kumar Mehata

Source: Wikipedia, the free encyclopedia.



Abhishesh Kumar Mehata (born April 16, 1992) is a

Sun pharmaceuticals research and development center. His area of research is to develop nanomedicine for the targeted therapy of breast cancer. He has more than 70 research publications in reputed international journals.[2][3][4]

Mehata has received a master's degree in

Frontiers in nanotechnology) and former student editor of Pharmstudent.[11]

His recently developed targeted

preclinical studies for breast cancer therapy.[12] He has also assisted the researcher in understanding immunological targeting for COVID-19 immunotherapy.[13]

References

  1. ^ "Loop | Abhishesh Kumar Mehata". loop.frontiersin.org. Retrieved 2022-01-23.
  2. ^ "Abhishesh kumar Mehata". scholar.google.co.in. Retrieved 2022-01-23.
  3. ^ "A. K. Mehata | Semantic Scholar". www.semanticscholar.org. Retrieved 2022-01-23.
  4. ^ "Abhishesh Kumar Mehata | Scinapse". www.scinapse.io. Retrieved 2022-01-24.
  5. ^ "msmuthu.phe | Indian Institute of Technology(BHU)". iitbhu.ac.in. Retrieved 2022-01-23.
  6. ^ "14 scientists from IIT-BHU in world's top 2% scientists' list by Stanford University". Deccan Herald. 2020-11-11. Retrieved 2022-01-23.
  7. ^ "14 scientists from IIT-BHU in world's top 2 pc scientists' list by Stanford University - Times of India". The Times of India. 11 November 2020. Retrieved 2022-01-23.
  8. ^ "Abhishesh Kumar Mehata - AD Scientific Index 2022". www.adscientificindex.com. Retrieved 2022-01-23.
  9. ^ "Editorial Board : Journal of Biomaterials". www.journalofbiomaterials.org. Retrieved 2022-01-23.
  10. ^ "cdtp - Editorial board". Hindawi. Retrieved 2024-04-12.
  11. ^ "Editorial Board". old.iitbhu.ac.in. Retrieved 2022-01-23.
  12. ^ "आईआईटी बीएचयू का झींगे से स्तन कैंसर की दवा बनाने का दावा". Hindustan (in Hindi). Retrieved 2022-01-23.
  13. PMID 34447458
    .